TIG:NGS-TiGenix

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 42.75

Change

+0.92 (+2.20)%

Market Cap

USD 253.14B

Volume

6.44K

Yahoo Analyst Target

USD 35.52 (-16.91%)

STA Analyst Target

USD 38.80 (-9.24%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

About

TiGenix NV is engaged in developing and commercializing novel therapeutics from its r proprietary technology platforms of allogeneic, or donor derived, stem cells.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2018-02-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
AMGN Amgen Inc.

-0.05 (-0.03%)

USD 132.26B
GILD Gilead Sciences Inc.

-0.85 (-1.04%)

USD 105.56B
CELG Celgene Corporation

-0.88 (-0.92%)

USD 71.65B
BIIB Biogen Inc.

-7.51 (-2.51%)

USD 61.75B
SHPG Shire plc

-1.24 (-0.92%)

USD 40.67B
VRTX Vertex Pharmaceuticals Incorpo..

-0.22 (-0.14%)

USD 40.65B
REGN Regeneron Pharmaceuticals Inc.

-1.03 (-0.31%)

USD 35.77B
ALXN Alexion Pharmaceuticals Inc.

-2.24 (-1.83%)

USD 26.71B
INCY Incyte Corporation

+0.44 (+0.51%)

USD 18.16B
GRFS Grifols S.A.

-0.07 (-0.30%)

USD 15.66B

ETFs Containing TIG

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 86.68% 97% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 86.68% 97% A+ 99% A+
Trailing 12 Months  
Capital Gain 185.95% 90% A- 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 185.95% 90% A- 98% A+
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 16.67% 62% D- 69% D+
Dividend Return 16.67% 62% D- 66% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 48.84% 51% F 22% F
Risk Adjusted Return 34.14% 66% D 45% F
Market Capitalization 2.51B 100% A+ 100% A+

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
(Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2,137.50 1% F 0% N/A
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
Price/Free Cash Flow Ratio N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -115.00% 25% F 9% F
Return on Invested Capital -50.67% 57% F 17% F
Return on Assets -49.58% 51% F 14% F
Debt to Equity Ratio 147.75% 9% F 15% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

TIG:NGS-TiGenix

EQUITY | Biotechnology | Nasdaq Global Select

Last Closing Price

USD 42.75

Change

+0.92 (+2.20)%

Market Cap

USD 253.14B

Volume

6.44K

Yahoo Analyst Target

USD 35.52 (-16.91%)

STA Analyst Target

USD 38.80 (-9.24%)
Yahoo Analyst Rating

Verdict

STA Analyst Rating

Verdict

STA Verdict

Verdict

Values as of: 2018-02-16